The Global Antibiotic Research and Development Partnership (GARDP) is a not-for-profit organization developing new treatments for drug-resistant infections that pose the greatest threat to health. We were created to ensure that everyone who needs antibiotics receives effective and affordable treatment, no matter where they live.
Read more »
We are proud of the progress we made in 2020 towards building an antibiotic portfolio and achieving our 5 BY 25 goal: to deliver five new treatments to tackle drug-resistant infections that pose the greatest threat to health by 2025.
a landmark observational study on neonatal sepsis and finalised a clinical study report on the pharmacokinetic clinical trial assessing the safety and dosing of fosfomycin in newborns.
one potential antibiotic combination of fosfomycin-amikacin to treat neonatal sepsis.
first agreement of GARDP’s Serious Bacterial Infections programme and started the first project to bring a new drug to market.
patient enrolment in the US and activated a new site in The Netherlands, as part of our phase 3 trial of a new treatment for gonorrhoea.
17 REVIVE webinars and launched a new online Antimicrobial Encyclopaedia.
over 24,000 compounds from five different partners. Daiichi Sankyo joined the GARDP-led Antimicrobial Resistance Screening Consortium alongside Eisai and Takeda.
Every year, 5.7 million people lose their lives because they cannot access the antibiotics they need— 8 times the number of deaths due to antibiotic resistance. To address this tragic problem, we urgently need a new access model for new and existing antibiotics.
Read more »
Most new antibiotics are unavailable in much of the world. Of the 25 new chemical entities (NCEs) developed between 1999 and 2014, only 12 have registered sales in more than ten countries. Shortages are likely to become increasingly common.
The poor access to antibiotics requires us to develop new concepts. GARDP has developed an access strategy that focuses on four pillars - evidence generation, early introduction, regulatory, and sustainable manufacturing and commercialisation. And with millions of lives at stake each year, we have no time to lose.
For young South African doctor Chelsea Kruger, working in a COVID-19 ward at the height of the first wave of the pandemic was compounded by the frightening reality of an outbreak of an antibiotic-resistant bacterial infection.
GARDP aims to build an antibiotic portfolio and deliver 5 new treatments by 2025 for drug-resistant infections that pose the greatest threat to health. GARDP is extremely grateful for the commitment of all its funders in helping us address the silent pandemic of drug-resistant infections.GARDP Partners
The 2020 Activity Report shows GARDP’s progress and promise in the fight against the most serious drug-resistant infections. It also demonstrates why more partnerships and investment are critical to address the growing threat of antibiotic resistance and achieve the Sustainable Development Goals.Download full report